NasdaqGS:DFTXPharmaceuticals
Definium Therapeutics Adds Commercial Leader As Phase 3 Milestones Approach
Definium Therapeutics (NasdaqGS:DFTX) appointed veteran biopharmaceutical executive Roger Adsett to its Board of Directors.
Adsett brings extensive experience in commercial strategy, operations, and the launch of multiple therapies.
The appointment comes as Definium Therapeutics prepares for three anticipated Phase 3 readouts.
For you as an investor, the key point is that Definium Therapeutics operates in the biopharmaceutical space, where late stage clinical milestones can be important...